YouTubeFacebookLinkedInTwitterinstagramrss

Creative Biolabs Announced Arcitumomab for Research Use



SHIRLEY, NY - Mar 18, 2020 - March 18, 2020, Creative Biolabs, as a leading supplier in the recombinant antibody field, announced the arcitumomab for research use. Since its establishment, Creative Biolabs has served more the two million customers from different country all over the world, providing high-quality and professional services and products. And Creative Biolabs also enjoyed a good fame among its loyal clients. Depending on the advanced technique platforms, including phage display platforms, Creative Biolabs is very confident in developing the most advanced and practical products, as well as a comprehensive list of recombinant antibody and extensive service portfolio at the most competitive price.

 

Arcitumomab is a biopharmaceutical preparation that selectively blocks platelet glycoprotein IIb / IIIa receptors and prevents fibrinogen, platelet agglutination factor, vitreous binding protein, and fibronectin from binding to activated platelets. Abciximab is suitable for percutaneous coronary angioplasty or atherectomy. It is an adjuvant treatment to prevent patients with sudden myocardial ischemia caused by coronary blockage. Patients at high risk of sudden blockages must be accompanied by at least one of the following: unstable angina pectoris or non-Q myocardial infarction; acute Q myocardial infarction that occurs within 12 hours; type II vascular injury during dilated arteries; Women over 65 years of age have type I vascular injury when dilating the arteries; diabetic patients have type I vascular injury when dilating the arteries or angioplasty related to myocardial infarction occurring within 7 days. In these cases, this product must be used with aspirin and heparin. Abciximab has antithrombotic activity against ongoing angioplasty and prevents vascular restenosis.

 

Because abciximab has an inhibitory effect on platelet aggregation, caution should be exercised when combined with other drugs that affect blood coagulation. These drugs include thrombolytic drugs, oral anticoagulants, non-steroidal anti-inflammatory drugs, and persantin.

 

“Creative Biolabs is able to develop more products like anti-Human CEA therapeutic Antibody fab fragment (arcitumomab), which is applied in the diagnostic imaging of colorectal cancers. The Fab' fragment of a monoclonal antibody and a radionuclide, technetium-99m are belonging to it. Arcitumomab is a Fab' fragment of IMMU-4, a murine IgG1 monoclonal antibody extracted from the ascites of mice. The enzyme pepsin cleaves the F(ab')2 fragment off the antibody.” said Dr. Peterson, a senior scientist of R&D in Creative Biolabs. 

 

“additionally, our arcitumomab is reconstituted with a solution of the radioactive agent sodium pertechnetate (99mTc) from a technetium generator before its application. It is our primary duty to offer high-quality product for researchers.” Dr. Peterson added.

 

About Creative Biolabs

With faith of providing high-quality products for the treatment of a wide variety of diseases, such as immune disorders, infections, cancers and more. And to build a custom-service-centered business model is the finial aim for all stuffs in the Creative Biolabs. And our long-term goal is to develop and provide the highest quality results to our clients and accelerate the pace of technology development.

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1